Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EMZ 702

Drug Profile

EMZ 702

Alternative Names: EMZ-702; EMZ702 + peginterferon-α + ribavirin; HCV-I.E.T.; HCV-IET; Interferon Enhancing Therapy for hepatitis C - Transition Therapeutics; Pegylated interferon-α + ribavirin + EMZ702

Latest Information Update: 08 Aug 2006

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Transition Therapeutics
  • Class Antivirals; Interferons; Ribonucleosides
  • Mechanism of Action Enzyme inhibitors; Immunomodulators; Interferon alpha stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Hepatitis C

Most Recent Events

  • 04 Aug 2006 Final results from a phase I/II clinical trial in patients with Hepatitis C have been added to the adverse events and Viral Infection therapeutic trials sections
  • 28 Apr 2006 Interim results from a phase I/II clinical trial in patients with Hepatitis C have been added to the Viral infections therapeutic trials section
  • 29 Jul 2005 Phase-I/II clinical trials in Hepatitis C treatment in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top